We are proud to share positive interim data of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy. Across two clinical trials – the SUNRISE-FA Phase 1/2 trial sponsored by Lexeo and a Phase 1A Weill Cornell Medicine investigator-initiated trial – LX2006 was well tolerated with no treatment-related serious adverse events, and clinically meaningful improvements in cardiac biomarkers were observed with increasing improvement over time. Read more here: https://lnkd.in/e2QD2YKA
Outstanding Lexeo Therapeutics and Eric Adler! Way to go and keep it up.
Great report out
Wonderful news. Congratulations!
Well done!
Innovative Leadership in Life Sciences & Technology Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies
1moThat's fantastic news, Lexeo Therapeutics! The positive interim data on LX2006 for treating Friedreich ataxia cardiomyopathy is truly promising. The results from both the SUNRISE-FA Phase 1/2 trial and the Weill Cornell Medicine Phase 1A trial show significant improvements in cardiac biomarkers without serious adverse events. This progress underscores the potential impact of LX2006 in improving patient outcomes. Looking forward to more updates on this important development!